268 related articles for article (PubMed ID: 29979634)
1. α-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease.
Miller JJ; Aoki K; Mascari CA; Beltrame AK; Sokumbi O; North PE; Tiemeyer M; Kriegel AJ; Dahms NM
FASEB J; 2019 Jan; 33(1):418-429. PubMed ID: 29979634
[TBL] [Abstract][Full Text] [Related]
2. Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease.
Miller JJ; Aoki K; Reid CA; Tiemeyer M; Dahms NM; Kassem IS
Sci Rep; 2019 Jun; 9(1):9392. PubMed ID: 31253878
[TBL] [Abstract][Full Text] [Related]
3. Neuropathic pain in a Fabry disease rat model.
Miller JJ; Aoki K; Moehring F; Murphy CA; O'Hara CL; Tiemeyer M; Stucky CL; Dahms NM
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563343
[TBL] [Abstract][Full Text] [Related]
4. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
5. Platelet and myeloid cell phenotypes in a rat model of Fabry disease.
Kanack AJ; Aoki K; Tiemeyer M; Dahms NM
FASEB J; 2021 Aug; 35(8):e21818. PubMed ID: 34320241
[TBL] [Abstract][Full Text] [Related]
6. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Sakiyama Y; Muramatsu K; Mizukami H
Hum Gene Ther; 2024 Mar; 35(5-6):192-201. PubMed ID: 38386497
[TBL] [Abstract][Full Text] [Related]
8. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.
Shen JS; Arning E; West ML; Day TS; Chen S; Meng XL; Forni S; McNeill N; Goker-Alpan O; Wang X; Ashcraft P; Moore DF; Cheng SH; Schiffmann R; Bottiglieri T
Hum Mol Genet; 2017 Mar; 26(6):1182-1192. PubMed ID: 28158561
[TBL] [Abstract][Full Text] [Related]
10. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Gupta S; Ries M; Kotsopoulos S; Schiffmann R
Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
[TBL] [Abstract][Full Text] [Related]
11. Progress in the understanding and treatment of Fabry disease.
Miller JJ; Kanack AJ; Dahms NM
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129437. PubMed ID: 31526868
[TBL] [Abstract][Full Text] [Related]
12. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
Ohshima T; Schiffmann R; Murray GJ; Kopp J; Quirk JM; Stahl S; Chan CC; Zerfas P; Tao-Cheng JH; Ward JM; Brady RO; Kulkarni AB
Proc Natl Acad Sci U S A; 1999 May; 96(11):6423-7. PubMed ID: 10339603
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
Desnick RJ; Banikazemi M; Wasserstein M
Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
15. Gastroenterological complications of Anderson-Fabry disease.
Buda P; Książyk J; Tylki-Szymanska A
Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
[TBL] [Abstract][Full Text] [Related]
16. Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease.
Hofmann L; Karl F; Sommer C; Üçeyler N
PLoS One; 2017; 12(6):e0180601. PubMed ID: 28662189
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.
Üçeyler N; Biko L; Hose D; Hofmann L; Sommer C
Mol Pain; 2016; 12():. PubMed ID: 27145802
[TBL] [Abstract][Full Text] [Related]
18. Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.
Jabbarzadeh-Tabrizi S; Boutin M; Day TS; Taroua M; Schiffmann R; Auray-Blais C; Shen JS
J Lipid Res; 2020 Nov; 61(11):1410-1423. PubMed ID: 32868283
[TBL] [Abstract][Full Text] [Related]
19. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
[TBL] [Abstract][Full Text] [Related]
20. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
